https://en.bioecon.ru/clusters/genome-engineering/Recent content in Genome-Engineering on BioeconHugoen-USFri, 24 Jul 2026 01:47:15 +0700https://en.bioecon.ru/technology/biosafety-lab-biosecurity/Thu, 23 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/biosafety-lab-biosecurity/Physical-containment infrastructure — biological safety cabinets, HEPA filtration, autoclave sterilization and BSL-1 to BSL-4 containment — that protects personnel, product and environment in every biotechnology laboratory, governed by NSF/ANSI 49 and EN 12469.https://en.bioecon.ru/technology/ecological-engineering-gene-drives/Mon, 06 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/ecological-engineering-gene-drives/Deliberately engineering whole wild populations — from CRISPR gene drives that force 100% inheritance of a trait through a mosquito population in 6-20 generations to Wolbachia-infected and radiation-sterilized releases that collapse it instead — as a genetic complement to nature-based ecological engineering like constructed wetlands and living shorelines, all governed by an irreversibility problem no field release can undo.https://en.bioecon.ru/technology/intelligent-genetic-switches-kill-switches/Sun, 05 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/intelligent-genetic-switches-kill-switches/Synthetic gene circuits that force engineered organisms to depend on external chemical signals for survival, self-destructing or losing viability once released into the environment — the biocontainment standard now required before any regulator clears a synthetic-biology product for open-system field trials.https://en.bioecon.ru/technology/xenobiology-expanded-genetic-alphabet/Sun, 05 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/xenobiology-expanded-genetic-alphabet/Orthogonal biological systems built on xeno-nucleic acids, unnatural base pairs and genomically recoded organisms that incorporate noncanonical amino acids into proteins — enabling site-specific drug conjugation and a genetic firewall against horizontal gene transfer with wild species.https://en.bioecon.ru/technology/epigenome-editing/Fri, 03 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/epigenome-editing/Turning genes on or off by rewriting DNA methylation and histone marks with dCas9 fusion proteins or zinc fingers — no DNA sequence change, but an effect that can be inherited across cell divisions.https://en.bioecon.ru/technology/minimal-genomes-synthetic-cells/Fri, 26 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/minimal-genomes-synthetic-cells/The frontier of building life de novo — stripping genomes down to a minimal viable chassis (top-down) and assembling artificial cells from non-living parts (bottom-up) to make predictable, biocontained cell factories.https://en.bioecon.ru/technology/prime-editing/Fri, 26 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/prime-editing/Search-and-replace genome editing with a Cas9 nickase fused to a reverse transcriptase and an extended pegRNA — writing all 12 base substitutions and small indels without a double-strand break.https://en.bioecon.ru/technology/synthetic-biology/Fri, 26 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/synthetic-biology/The engineering of biology — designing DNA, cells and genetic circuits on computers, building them in biofoundries and scaling them into chemicals, materials and ingredients through the Design-Build-Test-Learn cycle.https://en.bioecon.ru/technology/genome-editing/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/genome-editing/Programmable genome editors — CRISPR-Cas9, base editors and prime editors — delivered ex vivo or in vivo via lipid nanoparticles to treat genetic disease, from the first approved CRISPR therapy Casgevy to in-vivo redosable CRISPR and single-dose cardiovascular base editing.https://en.bioecon.ru/technology/base-editing/Fri, 19 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/base-editing/Base editors (CBE/ABE) make single-nucleotide changes C·G→T·A and A·T→G·C without double-strand breaks — treating monogenic disease (sickle cell, beta-thalassemia) at up to 90% efficiency with no indels.https://en.bioecon.ru/technology/crispr-screening-as-a-service/Fri, 19 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/crispr-screening-as-a-service/Contract functional-genetic CRISPR screening (pooled sgRNA libraries, lentiviral delivery, NGS) — identifies cancer-resistance genes and drug targets in weeks.